Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-23-0041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Ajay-Mohan Mohan und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
The mechanistic target of rapamycin complex 1 (mTORC1) inhibitor everolimus is one of the few approved therapies for locally advanced and metastatic neuroendocrine tumours (NETs). However, after initial disease stabilisation, most patients develop resistance within 1 year. Our aim was to overcome resistance to everolimus by additional treatment with the PI3K-alpha inhibitor alpelisib in an everolimus-resistant orthotopic pancreatic neuroendocrine carcinoma xenograft mouse model. Female SCID mice underwent laparoscopic pancreatic transplantation of everolimus-sensitive (BON1KDMSO) or everolimus-resistant (BON1RR2) NET cells. Both groups were further divided into four treatment groups: placebo, everolimus, alpelisib, and everolimus + alpelisib (combination). Oral treatment was started at a tumour volume of approximately 140 mm 3 and continued until 1900–2000 mm 3 , validated by weekly MRI. Somatostatin receptor expression and tumour viability were analysed by 68 Ga-DOTATOC and 18 F-FDG PET/CT. Everolimus resistance of the BON1RR2 tumours was confirmed. In the everolimus-sensitive group, everolimus alone, alpelisib alone, and combination treatment significantly prolonged survival, compared to placebo, while in the BON1RR2 group, only combination treatment significantly prolonged survival compared to placebo, but neither everolimus nor alpelisib alone. Placebo-treated everolimus-sensitive tumours grew more rapidly (median survival 45 days), compared to placebo-treated everolimus-resistant tumours (60 days). Within the everolimus-sensitive group, the combination-treated mice showed the longest median survival (52 days). Of all groups, the everolimus-resistant combination-treated group survived longest (69 days). Combination treatment with everolimus and alpelisib seems promising to overcome everolimus resistance in neuroendocrine neoplasms, and should be further examined in a clinical trial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Berlin Experimental Radionuclide Imaging Center (BERIC), Charité - Universitätsmedizin Berlin, Berlin, Germany.
- German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany.
- Department of Internal Medicine - Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany.
- Preclinical MRI Center, Charité - Universitätsmedizin Berlin, Berlin, Germany.
- Experimental and Clinical Research Center, Charité-Universitätsmedizin Berlin, and Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Translational Oncology of Solid Tumours, Berlin, Germany.
ORCID-Profile: Ajay-Mohan Mohan, Mathias Lukas, Matthias Ilmer, Katharina Wang, Karel Pacak, Ashley B Grossman, Svenja Nölting
Zitieren
APA
Mohan, A. M., Prasad, S., Schmitz-Peiffer, F., Lange, C., Lukas, M., Koziolek, E. J., Albrecht, J., Messroghli, D., Stein, U., Ilmer, M., Wang, K., Schober, L., Reul, A., Maurer, J., Friemel, J., Weber, A., Zuellig, R. A., Hantel, C., Fritsch, R., …, & Nölting, S. (2023). Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model. Endocrine-Related Cancer. https://doi.org/10.1530/erc-23-0041
Vancouver
Mohan AM, Prasad S, Schmitz-Peiffer F, Lange C, Lukas M, Koziolek EJ, et al. Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model. Endocrine-Related Cancer. 2023. doi:10.1530/erc-23-0041
BibTeX
@article{Mohan2023,
author = {Mohan, Ajay-Mohan and Prasad, Sonal and Schmitz-Peiffer, Fabian and Lange, Catharina and Lukas, Mathias and Koziolek, Eva J and Albrecht, Jakob and Messroghli, Daniel and Stein, Ulrike and Ilmer, Matthias and Wang, Katharina and Schober, Laura and Reul, Astrid and Maurer, Julian and Friemel, Juliane and Weber, Achim and Zuellig, Richard A and Hantel, Constanze and Fritsch, Ralph and Reincke, Martin and Pacak, Karel and Grossman, Ashley B and Auernhammer, Christoph J and Beuschlein, Felix and Brenner, Winfried and Beindorff, Nicola and Nölting, Svenja},
title = {Impact of the PI3K-alpha inhibitor alpelisib on everolimus resistance and somatostatin receptor expression in an orthotopic pancreatic NEC xenograft mouse model},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-23-0041}
}
EUVIMED